Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021;50(2):132-140.
doi: 10.1159/000513288. Epub 2021 Feb 2.

The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis

Maryam Honardoost  1   2 , Laila Janani  3 , Rokhsareh Aghili  1 , Zahra Emami  1 , Mohammad E Khamseh  4
Affiliations
Meta-Analysis

The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis

Maryam Honardoost et al. Cerebrovasc Dis. 2021.

Abstract

Aim: Several studies reported the accompaniment of severe COVID-19 with comorbidities. However, there is not a systematic evaluation of all aspects of this association. Therefore, this meta-analysis aimed to assess the association between all underlying comorbidities in COVID-19 infection severity.

Methods: Electronic literature search was performed via scientific search engines. After the removal of duplicates and selection of articles of interest, 28 studies were included. A fixed-effects model was used; however, if heterogeneity was high (I2 > 50%) a random-effects model was applied to combine the data.

Results: A total of 6,270 individuals were assessed (1,615 severe and 4,655 non-severe patients). The median age was 63 (95% confidence interval [CI]: 49-74) and 47 (95% CI: 19-63) years in the severe and non-severe groups, respectively. Moreover, about 41% of patients had comorbidities. Severity was higher in patients with a history of cerebrovascular disease: OR 4.85 (95% CI: 3.11-7.57). The odds of being in a severe group increase by 4.81 (95% CI: 3.43-6.74) for a history of cardiovascular disease (CVD). This was 4.19 (95% CI: 2.84-6.19) for chronic lung disease and 3.18, 95% CI: 2.09-4.82 for cancer. The odds ratios of diabetes and hypertension were 2.61 (95% CI: 2.02-3.3) and 2.37 (95% CI: 1.80-3.13), respectively.

Conclusions: The presence of comorbidities is associated with severity of COVID-19 infection. The strongest association was observed for cerebrovascular disease, followed by CVD, chronic lung disease, cancer, diabetes, and hypertension.

Keywords: COVID-19; Cardiovascular disorders; Cerebrovasular disease; Comorbid conditions; Disease severity.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
Flowchart of literature search and article selection.
Fig. 2
Fig. 2
Pooled prevalence of comorbidities in included studies. CVD, cardiovascular disease.
Fig. 3
Fig. 3
Prevalence of comorbid conditions among patients with severe COVID-19 compared with non-severe patients. CVD, cardiovascular disease; OR, odds ratio; CI, confidence interval.
Fig. 4
Fig. 4
Funnel plot for meta-analysis of the prevalence of comorbidity in COVID-19 patients. OR, odds ratio.
See this image and copyright information in PMC

References

    1. Leung C. Clinical features of deaths in the novel coronavirus epidemic in China. Rev Med Virol. 2020 May;30((3)):e2103. - PMC - PubMed
    1. Honardoost M, Ghavideldarestani M, Khamseh ME. Role of vitamin D in pathogenesis and severity of COVID-19 infection. Arch Physiol Biochem. 2020 Oct 30;:1–7. - PubMed
    1. Coronavirus disease (COVID-19) Weekly Epidemiological Update. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2....
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Mar 17;32((11)):1061–9. - PMC - PubMed
    1. AghiliHonardoost RM, Khamseh ME. COVID-19: case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities. Med J Islam Repub Iran. 2020;34((1)) - PMC - PubMed

Publication types

MeSH terms